Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma
The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Glioblastoma multiforme (GBM) is a lethal brain tumour in adults and children. However, DNA copy number and gene expression signatures indicate differences between adult and paediatric cases. To explore the genetic events underlying this distinction, we sequenced the exomes of 48 paediatric GBM samples. Somatic mutations in the H3.3-ATRX-DAXX chromatin remodelling pathway were identified in 44% of tumours (21/48). Recurrent mutations in H3F3A, which encodes the replication-independent histone 3 variant H3.3, were observed in 31% of tumours, and led to amino acid substitutions at two critical positions within the histone tail (K27M, G34R/G34V) involved in key regulatory post-translational modifications. Mutations in ATRX (α-thalassaemia/mental retardation syndrome X-linked) and DAXX (death-domain associated protein), encoding two subunits of a chromatin remodelling complex required for H3.3 incorporation at pericentric heterochromatin and telomeres, were identified in 31% of samples overall, and in 100% of tumours harbouring a G34R or G34V H3.3 mutation. Somatic TP53 mutations were identified in 54% of all cases, and in 86% of samples with H3F3A and/or ATRX mutations. Screening of a large cohort of gliomas of various grades and histologies (n = 784) showed H3F3A mutations to be specific to GBM and highly prevalent in children and young adults. Furthermore, the presence of H3F3A/ATRX-DAXX/TP53 mutations was strongly associated with alternative lengthening of telomeres and specific gene expression profiles. This is, to our knowledge, the first report to highlight recurrent mutations in a regulatory histone in humans, and our data suggest that defects of the chromatin architecture underlie paediatric and young adult GBM pathogenesis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Histone H3 lysine27-to-methionine (H3K27M) gain-of-function mutations occur in highly aggressive pediatric gliomas.”
From Histone H3 lysine-to-methionine mutants as a paradigm to study chromatin signaling (2014) · cites this paper as [3]
In the citing paper
“Indeed, the K27M mutation has been observed to occur in genes encoding all forms of histone H3 (H3.1, H3.2, and H3.3) in human glioma (1,10,24).”
From S -adenosyl methionine is necessary for inhibition of the methyltransferase G9a by the lysine 9 to methionine mutation on histone H3 (2016) · cites this paper as [1]
In the citing paper
“ALT is associated with mutations in the chromatin remodeller α-thalassaemia/mental retardation syndrome X-linked (AT R X ) both in vitro and in several human cancers, including glioblastomas162–165.”
From Telomeres in cancer: tumour suppression and genome instability (2017) · cites this paper as [163]
In the citing paper
“The H3.3G34R/V mutated tumours are found almost exclusively in the cerebral hemispheres 101,102 , whereas H3.1K27M tumours are restricted to an area of the brainstem called the pons and H3.3K27M tumours can also be found along the midline of the brain 106 .”
From The roles of DNA, RNA and histone methylation in ageing and cancer (2019) · cites this paper as [106]
In the citing paper
“A heterozygous point mutation of histone H3 occurs in more than 80% of these tumors, and results in a lysine-to-methionine substitution (H3K27M)2,3.”
From Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas (2017) · cites this paper as [2]
Citations
Cites
The Sequence Alignment/Map format and SAMtools
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., & 1000 Genome Project Data Processing Subgroup (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp352 · Cited by 62,041
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data
Wang, K., Li, M., & Hakonarson, H. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq603 · Cited by 14,621
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
A bivalent chromatin structure marks key developmental genes in embryonic stem cells
Bernstein, B. E., Mikkelsen, T. S., Xie, X., Kamal, M., Huebert, D. J., Cuff, J., Fry, B., Meissner, A., Wernig, M., Plath, K., et al. (2006) · Cell · doi:10.1016/j.cell.2006.02.041 · Cited by 5,361
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
Phillips, H. S., Kharbanda, S., Chen, R., Forrest, W. F., Soriano, R. H., Wu, T. D., Misra, A., Nigro, J. M., Colman, H., Soroceanu, L., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.02.019 · Cited by 3,143
Cited by
Items 801–900 of 1,001
Ehteda, A., Simon, S., Franshaw, L., Giorgi, F. M., Liu, J., Joshi, S. M., Rouaen, J. R. C., Pang, C. N. I., Pandher, R., Mayoh, C., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.108994 · Cited by 51
Cui, X., Zhang, C., Xu, Z., Wang, S., Li, X., Stringer-Reasor, E. M., Bae, S., Zeng, L., Zhao, D., Liu, R., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01472-x · Cited by 52
Self-citationMechanisms of Alternative Lengthening of Telomeres
O’Sullivan, R. J., & Greenberg, R. A. (2024) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a041690 · Cited by 59
Jiang, S., Wen, Z., Ahn, S. S., Cai, K., Paech, D., Eberhart, C. G., & Zhou, J. (2022) · NMR in Biomedicine · doi:10.1002/nbm.4731 · Cited by 48
ATRX and the replication of structured DNA
Clynes, D., & Gibbons, R. J. (2013) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2013.01.005 · Cited by 48
A histone H3K9M mutation traps histone methyltransferase Clr4 to prevent heterochromatin spreading
Shan, C., Wang, J., Xu, K., Chen, H., Yue, J., Andrews, S. J., Moresco, J. J., Yates, J. R., Nagy, P. L., Tong, L., et al. (2016) · eLife · doi:10.7554/elife.17903 · Cited by 49
“We further determined the crystal structure of an H3K9M peptide in complex with human H3K9 methyltransferase G9a and SAM, which reveales that the methionine side chain had enhanced van der Waals interactions with G9a.”
BackgroundTargeting Telomerase and ATRX/DAXX Inducing Tumor Senescence and Apoptosis in the Malignant Glioma
Fan, H., Chen, C., Chi, C.-S., Tsai, J., Chiang, K.-L., Chang, Y., Lin, S., & Harn, H. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20010200 · Cited by 50
“Mutations in the TERT promoter have been detected in 3–7% of pediatric GBM [44,123] and tumor cells in this group maintain or increase telomere length through alternative lengthening of telomeres (ALT) pathway [127,128].”
BackgroundChen, H., Hu, W., He, H., Yang, Y., Wen, G., & Lv, X. (2019) · European Journal of Radiology · doi:10.1016/j.ejrad.2019.03.006 · Cited by 48
Poon, W. S., Woo, P. M., Li, Y., Chan, A. Y., Ng, S. P., Loong, H. H.-F., Chan, D. M., & Wong, G. K. C. (2019) · Glioma · doi:10.4103/glioma.glioma_3_19 · Cited by 50
“[87] They are widely considered driver mutations in pediatric gliomagenesis with K27M mutant tumors predominantly seen in midline locations and G34V/R mutant tumors restricted to the cerebral hemispheres.[86,88] Epigenetic studies have shown that these histone modifications cause considerable DNA hypomethylation on a…”
BackgroundDaxx maintains endogenous retroviral silencing and restricts cellular plasticity in vivo
Wasylishen, A. R., Sun, C., Moyer, S. M., Qi, Y., Chau, G. P., Aryal, N. K., McAllister, F. M., Kim, M. P., Barton, M. C., Estrella, J. S., et al. (2020) · Science Advances · doi:10.1126/sciadv.aba8415 · Cited by 52
“3 (encoded by the H3F3A and H3F3B genes) were first identified in the invariably fatal pediatric malignancy diffuse intrinsic pontine glioma and have subsequently been identified in several other cancers (3, 4).”
Evaluating the transcriptional fidelity of cancer models
Peng, D., Gleyzer, R., Tai, W.-H., Kumar, P., Bian, Q., Isaacs, B., da Rocha, E. L., Cai, S., DiNapoli, K. T., Huang, F. W., et al. (2021) · Genome Medicine · doi:10.1186/s13073-021-00888-w · Cited by 51
“[120], GSE17537 [113], GSE23878 [121], GSE60697 [122], GSE37892 [123], GSE30540 [124], GSE50161 [125], GSE4290 [126], GSE60184 [127], GSE36245 [128], GSE53733 [129], GSE32374 [130], GSE34824 [131], GSE41137 [132], GSE53757 [133], GSE46699 [134], GSE36895 [135], GSE2109, GSE45436 [136], GSE9843 [137], GSE6222 [138], GS…”
Schüller, U., Iglauer, P., Dorostkar, M. M., Mawrin, C., Herms, J. W., Giese, A., Glatzel, M., & Neumann, J. E. (2021) · Acta Neuropathologica · doi:10.1007/s00401-020-02259-y · Cited by 51
“Diffuse midline glioma (DMG), H3 K27M mutant (WHO grade IV) is listed as a separate CNS tumor entity since 2016 [5], after large sequencing efforts had discovered H3 K27M mutations frequently appearing in gliomas located in midline structures [11].”
BackgroundGastroenteropancreatic endocrine tumors
Weil, C. (1985) · Journal of Molecular Medicine · doi:10.1007/bf01731493 · Cited by 50
Surveying the epigenomic landscape, one base at a time
Zentner, G. E., & Henikoff, S. (2012) · Genome biology · doi:10.1186/gb-2012-13-10-250 · Cited by 48
“Notably, mutations in nucleosome remodelers and in the histone constituents of chromatin have been implicated in human developmental disorders and cancer [6,7].”
BackgroundFuture of Clinical Genomics in Pediatric Oncology
Janeway, K. A., Place, A. E., Kieran, M. W., & Harris, M. H. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.8470 · Cited by 48
Molecularly Targeted Therapy for Neuroblastoma
Greengard, E. G. (2018) · Children · doi:10.3390/children5100142 · Cited by 47
Neuroendocrine neoplasms: current and potential diagnostic, predictive and prognostic markers
Herrera-Martínez, A. D., Hofland, L. J., Moreno, M. Á. G., Castano, J. P., de Herder, W. W., & Feelders, R. A. (2019) · Endocrine Related Cancer · doi:10.1530/erc-18-0354 · Cited by 51
Emerging roles of telomeric chromatin alterations in cancer
Cacchione, S., Biroccio, A., & Rizzo, A. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1030-5 · Cited by 52
Intratumoral Genetic and Functional Heterogeneity in Pediatric Glioblastoma
Hoffman, M., Gillmor, A. H., Kunz, D. J., Johnston, M. J. G., Nikolić, A., Narta, K., Zarrei, M., King, J., Ellestad, K. I., Dang, N. H., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3441 · Cited by 51
“Focusing specifically on nonsynonymous SNVs (nsSNV), our data are in agreement with previous reports of low mutation burden (3, 17, 18) in pGBM (range, 26–124 SNVs per tumor; average, 65.”
BackgroundResultCrowell, C., Mata‐Mbemba, D., Bennett, J., Matheson, K. J., Mackley, M. P., Perreault, S., & Erker, C. (2022) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdac133 · Cited by 57
“No mutation (amplification not assessed) 1 (1)”
BackgroundEpigenome Programming by H3.3K27M Mutation Creates a Dependence of Pediatric Glioma on SMARCA4
Mo, Y., Duan, S., Zhang, X., Hua, X., Zhou, H., Wei, H.-J., Watanabe, J., McQuillan, N., Su, Z., Gu, W. J., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1492 · Cited by 65
Glial Progenitors as Targets for Transformation in Glioma
Ilkhanizadeh, S., Lau, J., Huang, M., Foster, D. J., Wong, R. A., Frantz, A., Wang, S., Weiss, W. A., & Persson, A. I. (2014) · Advances in cancer research · doi:10.1016/b978-0-12-800249-0.00001-9 · Cited by 53
“ATRX mutations were more tightly associated with older patients and found in all tumors with G34 mutations in the Schwartzentruber et al study (Schwartzentruber et al., 2012; Sturm et al., 2012).”
BackgroundInfluentialPrognostic significance of telomere maintenance mechanisms in pediatric high-grade gliomas
Dorris, K. M. O., Sobo, M., Onar‐Thomas, A., Panditharatna, E., Stevenson, C. B., Gardner, S. L., DeWire, M. D., Pierson, C. R., Olshefski, R. S., Rempel, S. A., et al. (2014) · Journal of Neuro-Oncology · doi:10.1007/s11060-014-1374-9 · Cited by 48
“The prevalence and pattern of somatic H3F3A mutations in our cohort are generally consistent with prior studies [26, 28].”
A Review of Mathematical and Computational Methods in Cancer Dynamics
Uthamacumaran, A., & Zenil, H. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.850731 · Cited by 52
The Chromatin Remodeler ATRX: Role and Mechanism in Biology and Cancer
Pang, Y. K., Chen, X., Ji, T., Cheng, M., Wang, R., Zhang, C., Liu, M., Zhang, J., & Zhong, C. (2023) · Cancers · doi:10.3390/cancers15082228 · Cited by 51
“Furthermore, ATRX mutations were identified in 31% of individuals with primary GBM (WHO grade IV glioma) [16].”
BackgroundSelf-citationH3K36 methylation maintains cell identity by regulating opposing lineage programmes
Hoetker, M. S., Yagi, M., Stefano, B. D., Langerman, J., Cristea, S., Wong, L. P., Huebner, A. J., Charlton, J., Deng, W., Haggerty, C., et al. (2023) · Nature Cell Biology · doi:10.1038/s41556-023-01191-z · Cited by 47
Martinez, P. J., Nault, G., Steiner, J., Wempe, M. F., Pierce, A. M., Brunt, B., Slade, M., Song, J. J., Mongin, A., Song, K.-H., et al. (2023) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdad111 · Cited by 57
Ross, J. L., Vallcorba, M. P., Piñero, G., Soni, N., Thomason, W., DeSisto, J. A., Angione, A., Tsankova, N. M., Castro, M. G., Schniederjan, M., et al. (2024) · Immunity · doi:10.1016/j.immuni.2024.09.007 · Cited by 49
Diffuse Intrinsic Pontine Glioma: Time for Cautious Optimism
Hennika, T., & Becher, O. J. (2015) · Journal of Child Neurology · doi:10.1177/0883073815601495 · Cited by 54
“These mutations result in an amino acid substitution conferring a change in lysine to methionine at position 27 on the histone tail (K27M).(5,6,11) This lysine-to-methionine substitution confers global loss of trimethylation at lysine 27 of histone H3 (H3K27me3), which profoundly alters gene expression as H3K27me3 is…”
BackgroundManganese-containing Prussian blue nanoparticles for imaging of pediatric brain tumors
Fernandes, R., Dumont, M., Yadavilli, S., Sze, R. W., & Nazarian, J. (2014) · International Journal of Nanomedicine · doi:10.2147/ijn.s63472 · Cited by 54
The PML-Interacting Protein DAXX: Histone Loading Gets into the Picture
Salomoni, P. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00152 · Cited by 51
“3 mutations, as observed in adult GBM, neuroblastoma and pancreatic tumors, suggesting that alterations in loading of WT H3.”
BackgroundInfluentialGliomas Genomics and Epigenomics: Arriving at the Start and Knowing It for the First Time
Filbin, M. G., & Suvà, M. L. (2016) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-012615-044208 · Cited by 51
“F or p er so na l u se o nl y. ATRX / DAXX mutation TERT promoter mutation ATRX DAXX Histone 3.3 ATRX DAXX Histone 3.3 Telomerase Telomerase a b Figure 2 Telomere maintenance in glioma.”
InfluentialDistinct Histomorphology in Molecular Subgroups of Glioblastomas in Young Patients
Neumann, J. E., Dorostkar, M. M., Korshunov, A., Mawrin, C., Koch, A., Giese, A., & Schüller, U. (2016) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlw015 · Cited by 48
“Mutations in the chromatin modifier Histone 3 (H3) have also been detected in a number of GBMs (5), with K27M mutations almost exclusively occurring in midline tumors (6).”
BackgroundSelf-citationFeng, Z., Wang, L., Sun, Y., Jiang, Z., Domsic, J. F., An, C., Xing, B., Tian, J., Liu, X., Metz, D. C., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-1567 · Cited by 46
Self-citationLife and cancer without telomerase: ALT and other strategies for making sure ends (don’t) meet
Apte, M. S., & Cooper, J. P. (2016) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409238.2016.1260090 · Cited by 47
“Mutation or deletion of ATRX (and to lesser extent DAXX) is found both in ALT cell lines and tumors, including pancreatic neuroendocrine tumors, pediatric glioblastomas, neuroblastomas, and medulloblastomas (Heaphy et al., 2011a; Lovejoy et al., 2012; Schwartzentruber et al., 2012).”
BackgroundReview of molecular classification and treatment implications of pediatric brain tumors
Stücklin, A. G., Ramaswamy, V., Daniels, C., & Taylor, M. D. (2017) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000000562 · Cited by 53
Kazantseva, M., Eiholzer, R. A., Mehta, S. Y., Taha, A. J., Bowie, S., Roth, I. M., Zhou, J., Joruiz, S. M., Royds, J. A., Hung, N. A., et al. (2018) · The Journal of Pathology · doi:10.1002/path.5111 · Cited by 51
Genomic and transcriptomic characterisation of undifferentiated pleomorphic sarcoma of bone
Ali, N. M., Niada, S., Brini, A. T., Morris, M. R., Kurusamy, S., Alholle, A., Huen, D. S., Antonescu, C. R., Tirode, F., Sumathi, V. P., et al. (2018) · The Journal of Pathology · doi:10.1002/path.5176 · Cited by 49
“A significant co-occurrence of the G34 H3F3A mutation with ATRX/DAXX and TP53 mutations has been observed in nearly 100% of glioblastoma tumours [19].”
BackgroundInfluentialHamisch, C., Minartz, J., Blau, T., Hafkemeyer, V., Ruess, D. F., Hellerbach, A., Grau, S., & Ruge, M. I. (2019) · Acta Neurochirurgica · doi:10.1007/s00701-019-04020-1 · Cited by 48
Diffuse midline glioma: review of epigenetics
Cooney, T. M., Lubanszky, E., Prasad, R., Hawkins, C. E., & Mueller, S. (2020) · Journal of Neuro-Oncology · doi:10.1007/s11060-020-03553-1 · Cited by 50
Tumour immune landscape of paediatric high-grade gliomas
Ross, J. L., Vega, J. E. V., Plant, A., MacDonald, T. J., Becher, O. J., & Hambardzumyan, D. (2021) · Brain · doi:10.1093/brain/awab155 · Cited by 48
Zhang, Y., Chang, J.-F., Sun, J., Chen, L., Yang, X.-M., Tang, H.-Y., Jing, Y.-Y., Kang, X., He, Z.-M., Wu, J.-Y., et al. (2018) · Journal of Cell Science · doi:10.1242/jcs.215525 · Cited by 45
“3K27M mutations were discovered in over 70% of DIPG patients, exogenous expression of H3.”
BackgroundInfluentialImaging characteristics of H3 K27M histone-mutant diffuse midline glioma in teenagers and adults
Thust, S. C., Micallef, C., Okuchi, S., Brandner, S., Kumar, A., Mankad, K., Wastling, S. J., Mancini, L., Jäger, H. R., & Shankar, A. (2020) · Quantitative Imaging in Medicine and Surgery · doi:10.21037/qims-19-954 · Cited by 46
“Histone octamers, consisting of paired H2A, H2B, H3, and H4 subunits, contain terminal protein terminals as the access point for post-translational modification (6).”
BackgroundAnwer, M. S., Abdel-Rasol, M. A., & El-Sayed, W. M. (2025) · Clinical and Experimental Medicine · doi:10.1007/s10238-025-01631-0 · Cited by 46
“Methylation of lysine residues on histones can mark chromatin regions as either active (K4, K36, K39) or inactive (K9, K27), thus influencing gene transcription [48].”
Mur, P., Mollejo, M., Hernández‐Iglesias, T., de Lope, Á. R., Castresana, J. S., García, J. F., Fiaño, C., Ribalta, T., REY, J. A., & Meléndez, B. (2015) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0000000000000167 · Cited by 46
“have been reported in adult as well as childhood gliomas (17, 19, 21, 31, 32).”
BackgroundPrognostic and Predictive Biomarkers in Adult and Pediatric Gliomas: Toward Personalized Treatment
Haynes, H. R., Camelo-Piragua, S. I., & Kurian, K. M. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00047 · Cited by 51
“Such supratentorial tumors occur in an older population (median 18 years) and almost always overlap with TP53 and ATRX mutations (142).”
BackgroundInfluentialLee, J. C., Solomon, D. A., & Tihan, T. (2017) · Journal of Neuro-Oncology · doi:10.1007/s11060-016-2349-9 · Cited by 49
“G34R/V and K27M mutations both show mutation-specific gene expression profiles, with distinctive expression patterns similar to those observed during normal brain development [1, 31, 33].”
BackgroundInfluentialUpadhyay, P., Gardi, N., Desai, S., Chandrani, P., Joshi, A., Dharavath, B., Arora, P., Bal, M. M., Nair, S. V., & Dutt, A. (2017) · Oral Oncology · doi:10.1016/j.oraloncology.2017.08.003 · Cited by 45
“%) not associated with tobacco [31] and consistent with reports in HNSCC [6,28].”
New Directions in the Treatment of Glioblastoma
Reitman, Z. J., Winkler, F., & Elia, A. E. H. (2018) · Seminars in Neurology · doi:10.1055/s-0038-1623534 · Cited by 48
A rapid genotyping panel for detection of primary central nervous system lymphoma
Gupta, M., Burns, E. J., Georgantas, N. Z., Thierauf, J., Nayyar, N., Gordon, A., Jones, S. S., Pisapia, M., Sun, Y., Burns, R. P., et al. (2021) · Blood · doi:10.1182/blood.2020010137 · Cited by 45
Oncohistones: a roadmap to stalled development
Deshmukh, S., Ptack, A., Krug, B., & Jabado, N. (2021) · FEBS Journal · doi:10.1111/febs.15963 · Cited by 49
Self-citationLietz, C. E., Newman, E. T., Kelly, A. D., Xiang, D. H., Zhang, Z., Luscko, C. A., Lozano‐Calderón, S. A., Ebb, D. H., Raskin, K. A., Cote, G. M., et al. (2022) · Communications Biology · doi:10.1038/s42003-022-03117-1 · Cited by 47
Overview of DNA methylation in adult diffuse gliomas
Aoki, K., & Natsume, A. (2019) · Brain Tumor Pathology · doi:10.1007/s10014-019-00339-w · Cited by 47
Jha, P., Agrawal, R., Pathak, P., Kumar, A., Purkait, S., Mallik, S., Suri, V., Chand Sharma, M., Gupta, D., Suri, A., et al. (2015) · International Journal of Cancer · doi:10.1002/ijc.29610 · Cited by 44
“3 is another important genetic event unique to pediatric GBMs.(7) Mutation in the H3F3A gene raised huge interest owing to its crucial role in the chromatin remodeling pathway and regulation of epigenetic mechanisms.”
BackgroundResultInfluentialBeyes, S., Bediaga, N. G., & Zippo, A. (2021) · Cancers · doi:10.3390/cancers13194969 · Cited by 50
“3 variants (H3K27M), identified in paediatric high-grade gliomas (HGG) [44].”
BackgroundInfluentialDecoding Diffuse Midline Gliomas: A Comprehensive Review of Pathogenesis, Diagnosis and Treatment
Sharie, S. A., Laban, D. A., & Al-Hussaini, M. A. (2023) · Cancers · doi:10.3390/cancers15194869 · Cited by 48
“DMGs are highly aggressive and tend to infiltrate surrounding brain tissue, making any attempt at surgical removal nearly impossible [19,20].”
Backgroundvan den Bent, M. J., Saratsis, A. M., Geurts, M., & Franceschi, E. (2023) · Neuro-Oncology · doi:10.1093/neuonc/noad220 · Cited by 46
“The discovery of the somatic H3 K27M mutation was re-ported in 2 independent publications in 2012, using exome sequencing of pediatric glioblastomas 27 and whole-genome sequencing of DIPG samples.”
BackgroundBrocato, J., Fang, L., Chervona, Y., Chen, D., Kiok, K., Sun, H., Tseng, H.-C., Xu, D., SHAMY, M. Y., Jin, C., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.591883 · Cited by 44
Role of epigenetic mechanisms in epithelial-to-mesenchymal transition of breast cancer cells
Nickel, A., & Stadler, S. C. (2014) · Translational research · doi:10.1016/j.trsl.2014.04.001 · Cited by 48
The transcription factor Olig2 is important for the biology of diffuse intrinsic pontine gliomas
Anderson, J. L., Muraleedharan, R., Oatman, N., Klotter, A., Sengupta, S., Waclaw, R. R., Wu, J., Drissi, R., Miles, L., Raabe, E. H., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now299 · Cited by 47
National cancer database analysis of outcomes in pediatric glioblastoma
Liu, M., Thakkar, J. P., García, C. R., Dolecek, T. A., Wagner, L. M., Dressler, E. V. M., & Villano, J. L. (2018) · Cancer Medicine · doi:10.1002/cam4.1404 · Cited by 45
“As previously stated, H3F3A mutations are frequent in centrally located tumors [6], these mutations largely overlap with TP53 mutations [40], that have been linked with a diminished response to radiation [41–43].”
BackgroundQi, J., Esfahani, D. R., Huang, T., Ozark, P. A., Bartom, E. T., Hashizume, R., Bonner, E. R., An, S., Horbinski, C., James, C. D., et al. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0727-1 · Cited by 46
H3 G34-mutant high-grade glioma
Lim, K. Y., Won, J., Park, C., Kim, S., Choi, S. H., Kim, T., Yun, H., & Park, S. (2020) · Brain Tumor Pathology · doi:10.1007/s10014-020-00378-8 · Cited by 46
Pediatric Glioma: An Update of Diagnosis, Biology, and Treatment
Funakoshi, Y., Hata, N., Kuga, D., Hatae, R., Sangatsuda, Y., Fujioka, Y., Takigawa, K., & Mizoguchi, M. (2021) · Cancers · doi:10.3390/cancers13040758 · Cited by 49
“3, occurs in pHGGs of the cerebral cortex [85,86,88], whereas the G34W mutation is prevalent in bone tumors [94].”
BackgroundPark, Y. W., Vollmuth, P., Foltyn‐Dumitru, M., Sahm, F., Ahn, S. S., Chang, J. H., & Kim, S. H. (2023) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.28740 · Cited by 46
“3 mutation was also noted in non-brainstem glioblastomas.(15,16) This led to the newly defined entity at the 2016 WHO classification termed “diffuse midline glioma, H3 K27M-mutant.”
BackgroundMorozov, V. M., Gavrilova, E. V., Ogryzko, V. V., & Ishov, A. M. (2012) · Nucleus · doi:10.4161/nucl.20180 · Cited by 51
Chromatin dynamics: H3K4 methylation and H3 variant replacement during development and in cancer
Deb, M., Kar, S., Sengupta, D., Shilpi, A., Parbin, S., Rath, S. K., Londhe, V. A., & Patra, S. K. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1605-4 · Cited by 48
“H3F3A/ATRX–DAXX/TP53 mutations in glioblastoma alter telomere lengths and result in irregular gene expression [24].”
BackgroundExploration of Interfacial Hydration Networks of Target–Ligand Complexes
Jeszenői, N., Bálint, M., Horváth, I., van der Spoel, D., & Hetényi, C. (2015) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5b00638 · Cited by 43
DNA mismatch repair preferentially safeguards actively transcribed genes
Huang, Y., & Li, G. (2018) · DNA repair · doi:10.1016/j.dnarep.2018.08.010 · Cited by 47
Rapid and reversible suppression of ALT by DAXX in osteosarcoma cells
Yost, K. E., Soper, S. F. C., Walker, R. L., Pineda, M. A., Zhu, Y. J., Ester, C. D., Showman, S., Roschke, A. V., Waterfall, J. J., & Meltzer, P. S. (2019) · Scientific Reports · doi:10.1038/s41598-019-41058-8 · Cited by 45
Karlowee, V., Amatya, V. J., Takayasu, T., Takano, M., Yonezawa, U., Takeshima, Y., Sugiyama, K., Kurisu, K., & Yamasaki, F. (2019) · Pathobiology · doi:10.1159/000496691 · Cited by 46
The Role of Polycomb Repressive Complex in Malignant Peripheral Nerve Sheath Tumor
Zhang, X., Murray, B., Mo, G., & Shern, J. F. (2020) · Genes · doi:10.3390/genes11030287 · Cited by 46
“This mechanism is most notable in diffuse intrinsic pontine gliomas and pediatric non-brainstem high-grade gliomas, where mutation in histone H3 yields variant, K27M, that binds and mislocalizes PRC2 in addition to inhibiting its function [41,42].”
BackgroundWang, J., Yang, L., Dong, C., Wang, J., Xu, L., Qiu, Y., Weng, Q., Zhao, C., Xin, M., & Lu, Q. R. (2020) · Science Advances · doi:10.1126/sciadv.aaz6477 · Cited by 46
Epigenomics and immunotherapeutic advances in pediatric brain tumors
Abedalthagafi, M., Mobark, N. A., Alrashed, M. M., & Alharbi, M. (2021) · npj Precision Oncology · doi:10.1038/s41698-021-00173-4 · Cited by 45
“Oncolytic viruses have more advantages than standard therapies, including (1) the selective infection and replication in cancer cells, (2) the lack of resistance from tumor cells, (3) the virus spreads throughout the tumor after a few cells have been infected, and (4) the virus can trigger an immune response against t…”
BackgroundH3.3K27M Mutation Controls Cell Growth and Resistance to Therapies in Pediatric Glioma Cell Lines
Rakotomalala, A., Bailleul, Q., Savary, C., Arcicasa, M., Hamadou, M., Huchedé, P., Hochart, A., Restouin, A., Castellano, R., Collette, Y., et al. (2021) · Cancers · doi:10.3390/cancers13215551 · Cited by 44
“Furthermore, H3G34R/V mutations are observed in supratentorial pediatric HGGs, and cause other epigenetic alterations responsible for aberrant transcriptional programs in these cancers [9,12,23,24].”
BackgroundOncohistones: Hijacking the Histone Code
Sahu, V., & Lü, C. (2022) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-070120-102521 · Cited by 43
Keck, M., Sill, M., Wittmann, A., Joshi, P. K., Stichel, D., Beck, P., Okonechnikov, K., Sievers, P., Wefers, A. K., Roncaroli, F., et al. (2022) · Acta Neuropathologica · doi:10.1007/s00401-022-02516-2 · Cited by 48
Self-citationMolecular Genetics and Targeted Therapies for Paediatric High-grade Glioma
Rallis, K. S., George, A. M., Wozniak, A. M., Bigogno, C. M., Chow, B., HANRAHAN, J. G., & Sideris, M. C. (2022) · Cancer Genomics & Proteomics · doi:10.21873/cgp.20328 · Cited by 55
Fahmy, S. A., Dawoud, A., Zeinelabdeen, Y. A., Kiriacos, C. J., Daniel, K. A., Eltahtawy, O., Abdelhalim, M. M., Braoudaki, M., & Youness, R. A. (2022) · Cancers · doi:10.3390/cancers14215244 · Cited by 42
“In addition, the proposed NPs showed multimodal anticancer activities against U87MG, and P3#GBM brain cancer cells via (i) activating reduced nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, leading to increasing hydrogen peroxide levels, (ii) increasing the intracellular iron levels which will eventually…”
BackgroundSoni, S., Pchelintsev, N. A., Adams, P. D., & Bieker, J. J. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1405422111 · Cited by 42
“3, is mutated in pediatric malignant brain tumors and that these mutations are proposed to drive tumor formation (8, 9).”
BackgroundAhsan, S., Raabe, E. H., Haffner, M. C., Vaghasia, A. M., Warren, K. E., Quezado, M., Ballester, L. Y., Nazarian, J., Eberhart, C. G., & Rodríguez, F. J. (2014) · Acta Neuropathologica Communications · doi:10.1186/2051-5960-2-59 · Cited by 43
“Therefore, as a result of the K27M mutation, histone methylation is decreased at this site [8,9,13,10].”
InfluentialAltered primary chromatin structures and their implications in cancer development
Ferraro, A. (2016) · Cellular Oncology · doi:10.1007/s13402-016-0276-6 · Cited by 45
The histone variant H3.3 claims its place in the crowded scene of epigenetics
Bano, D., Piazzesi, A., Salomoni, P., & Nicotera, P. (2017) · Aging · doi:10.18632/aging.101194 · Cited by 46
“Moreover, ATRX is mutated in astrocytic tumours [85], HGG and in neuroblastoma, whilst DAXX deficiency has been linked to a few cases of paediatric HGG, with a mutually exclusive pattern to ATRX mutations [30, 65, 86].”
BackgroundAlternative Lengthening of Telomeres (ALT) in Tumors and Pluripotent Stem Cells
Zhao, S., Wang, F., & Liu, L. (2019) · Genes · doi:10.3390/genes10121030 · Cited by 43
Perla, A., Fratini, L., Cardoso, P. S., Nör, C., Brunetto, A. T., Brunetto, A. L., de Farias, C. B., Jaeger, M. D. C., & Roesler, R. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00546 · Cited by 47
Vuong, H. G., Le, H. T., Ngo, T. N. M., Fung, K., Battiste, J. D., McNall‐Knapp, R. Y., & Dunn, I. F. (2021) · Journal of Neuro-Oncology · doi:10.1007/s11060-021-03890-9 · Cited by 43
Therapeutic Targets in Diffuse Midline Gliomas—An Emerging Landscape
Hayden, E., Holliday, H., Lehmann, R. J., Khan, A., Tsoli, M., Rayner, B. S., & Ziegler, D. S. (2021) · Cancers · doi:10.3390/cancers13246251 · Cited by 45
Mutational Landscape and Outcomes of Conjunctival Melanoma in 101 Patients
Lally, S. E., Milman, T., Orloff, M. M., Dalvin, L. A., Eberhart, C. G., Heaphy, C. M., Rodríguez, F. J., Lin, C., Dockery, P. W., Shields, J. A., et al. (2022) · Ophthalmology · doi:10.1016/j.ophtha.2022.01.016 · Cited by 44
Consequences of telomere replication failure: the other end-replication problem
Brenner, K. A., & Nandakumar, J. (2022) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2022.03.013 · Cited by 36
Tomita, Y., Shimazu, Y., Somasundaram, A., Tanaka, Y., Takata, N., Ishi, Y., Gadd, S., Hashizume, R., Angione, A., Piñero, G., et al. (2022) · Glia · doi:10.1002/glia.24189 · Cited by 56
Structural variants shape driver combinations and outcomes in pediatric high-grade glioma
Dubois, F. P. B., Shapira, O., Greenwald, N. F., Zack, T. I., Wala, J. A., Tsai, J. W., Crane, A., Baguette, A., Hadjadj, D., Harutyunyan, A. S., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00403-z · Cited by 47
Self-citationChang, Y., Wu, Q., Tian, T., Li, L., Guo, X., Feng, Z., Zhou, J., Zhang, L., Zhou, S., Feng, G., et al. (2015) · Tumor Biology · doi:10.1007/s13277-015-3289-2 · Cited by 43
“Gene mutations [1], genomic instability [2], deregulation of signaling pathways, and alternative splicing can all influence the occurrence and development of tumors.”
BackgroundImmunotherapy approaches for the treatment of diffuse midline gliomas
Bernstock, J. D., Hoffman, S. E., Kappel, A. D., Valdes, P. A., Essayed, W. I., Klinger, N. V., Kang, K., Totsch, S. K., Olsen, H. E., Schlappi, C., et al. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2124058 · Cited by 44
“3K27M has inspired multiple studies investigating its use in APC vaccines that will inform the utility of this strategy.(15,68,92,93)”
BackgroundHIRA vs. DAXX: the two axes shaping the histone H3.3 landscape
Choi, J., Kim, T., & Cho, E. (2024) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-01145-3 · Cited by 42
Human Embryonic Stem Cells: A Model for the Study of Neural Development and Neurological Diseases
Prajumwongs, P., Weeranantanapan, O., Jaroonwitchawan, T., & Noisa, P. (2016) · Stem Cells International · doi:10.1155/2016/2958210 · Cited by 48
Baugh, J., Bartels, U. K., Leach, J. L., Jones, B. V., Chaney, B., Warren, K. E., Kirkendall, J., Doughman, R., Hawkins, C. E., Miles, L., et al. (2017) · Journal of Neuro-Oncology · doi:10.1007/s11060-017-2372-5 · Cited by 44
“In 2012, next-generation sequencing studies using autopsy and some biopsy tissue elucidated the genomic landscape of DIPG [9, 10].”
BackgroundSelf-citationIdentification of a novel gene fusion in ALT positive osteosarcoma
Mason‐Osann, E., Dai, A., Floro, J., Lock, Y. J., Reiss, M., Gali, H., Matschulat, A. M., Labadorf, A. T., & Flynn, R. L. (2018) · Oncotarget · doi:10.18632/oncotarget.26029 · Cited by 43
Pituitary Adenoma in Pediatric and Adolescent Populations
Chen, J., Schmidt, R. E., & Dahiya, S. M. (2019) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlz040 · Cited by 41
PRC2 engages a bivalent H3K27M-H3K27me3 dinucleosome inhibitor
Diehl, K. L., Ge, E. J., Weinberg, D. N., Jani, K. S., Allis, C. D., & Muir, T. W. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1911775116 · Cited by 44
“A mixture of PRC2 core complex (300 nM) and a FLIP, H3(1-37) K27Nva-PEG-FAM (100 nM) in binding buffer (50 mM Hepes pH 8, 50 mM NaCl, 2 mM MgCl2, at 1 mM DTT, at 20 °C) was titrated with either SAM or SP to determine the apparent binding constants for these ligands.”
MethodThe Power of Human Cancer Genetics as Revealed by Low-Grade Gliomas
Jones, D., Bandopadhayay, P., & Jabado, N. (2019) · Annual Review of Genetics · doi:10.1146/annurev-genet-120417-031642 · Cited by 52
Self-citation
Metadata
- Authors
- Schwartzentruber, J., Korshunov, A., Liu, X.-Y., Jones, D. T. W., Pfaff, E., Jacob, K., Sturm, D., Fontebasso, A. M., Quang, D.-A. K., Tönjes, M., Hovestadt, V., Albrecht, S., Kool, M., Nantel, A., Konermann, C., Lindroth, A., Jäger, N., Rausch, T., Ryzhova, M., Korbel, J. O., Hielscher, T., Hauser, P., Garami, M., Klekner, A., Bognar, L., Ebinger, M., Schuhmann, M. U., Scheurlen, W., Pekrun, A., Frühwald, M. C., Roggendorf, W., Kramm, C., Dürken, M., Atkinson, J., Lepage, P., Montpetit, A., Zakrzewska, M., Zakrzewski, K., Liberski, P. P., Dong, Z., Siegel, P., Kulozik, A. E., Zapatka, M., Guha, A., Malkin, D., Felsberg, J., Reifenberger, G., von Deimling, A., Ichimura, K., Collins, V. P., Witt, H., Milde, T., Witt, O., Zhang, C., Castelo-Branco, P., Lichter, P., Faury, D., Tabori, U., Plass, C., Majewski, J., Pfister, S. M., & Jabado, N.
- Affiliations
- McGill University and Génome Québec Innovation Centre (CA)
- German Cancer Research Center (DE)
- McGill University (CA)
- Montreal Children's Hospital (CA)
- European Molecular Biology Laboratory (DE)
- Burdenko Neurosurgery Institute (RU)
- University Children's Hospital Tübingen (DE)
- Universitätsklinikum Tübingen (DE)
- Cnopf´sche Kinderklinik (DE)
- Prof. Hess Kinderklinik (DE)
- University Hospital Augsburg (DE)
- University of Würzburg (DE)
- University Hospital in Halle (DE)
- Medical University of Lodz (PL)
- University Hospital Heidelberg (DE)
- University of Toronto (CA)
- Heinrich Heine University Düsseldorf (DE)
- University of Cambridge (GB)
- McGill University Health Centre (CA)
- Corresponding author
- Majewski, Jacek
- Pfister, Stefan M.
- Jabado, Nada
- ORCID
- Schwartzentruber, Jeremy
- Korshunov, Andrey
- Jones, David T. W.
- Pfaff, Elke
- Sturm, Dominik
- Hovestadt, Volker
- Albrecht, Steffen
- Kool, Marcel
- Lindroth, Anders
- Jäger, Natalie
- Rausch, Tobias
- Ryzhova, Marina
- Korbel, Jan O.
- Hielscher, Thomas
- Ebinger, Martin
- Schuhmann, Martin U.
- Frühwald, Michael C.
- Dürken, Matthias
- Atkinson, Jeffrey
- Lepage, Pierre
- Zakrzewska, Magdalena
- Liberski, Pawel P.
- Siegel, Peter
- Kulozik, Andreas E.
- Zapatka, Marc
- Guha, Abhijit
- Malkin, David
- Felsberg, Jörg
- Reifenberger, Guido
- Ichimura, Koichi
- Collins, V. Peter
- Witt, Hendrik
- Milde, Till
- Witt, Olaf
- Zhang, Cindy
- Lichter, Peter
- Faury, Damien
- Tabori, Uri
- Plass, Christoph
- Majewski, Jacek
- Pfister, Stefan M.
- Jabado, Nada
- Venue
- Nature
- Published
- 2012-01-29
- Volume
- 482
- Issue
- 7384
- Pages
- 226-231
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2158233796
- Cited by
- 2,631
- References
- 35
- Citations by year
- 2026: 109 · 2025: 138 · 2024: 188 · 2023: 189 · 2022: 200 · 2021: 226 · 2020: 238 · 2019: 188 · 2018: 166 · 2017: 200 · 2016: 174 · 2015: 165 · 2014: 189 · 2013: 166 · 2012: 90
- FWCI
- 92.99
- Type
- journal article
- Language
- en
- Update notices
- erratum (2012-03-28)
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Repository of the Academy's Library (Library of the Hungarian Academy of Sciences) (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- NPARC (submittedVersion)
- University of Debrecen Electronic Archive (University of Debrecen) (submittedVersion)
- Semmelweis University Repository (Semmelweis University) (submittedVersion)
- OPUS (Augsburg University) (submittedVersion)
- Funders
- Cancer Research Institute
- Genome Canada
- Brain Tumour Charity (10/106)
- Canadian Institutes of Health Research
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- H3F3A mutation, histone H3.3, ATRX mutation, chromatin remodeling, somatic mutations, TP53 mutation, H3K27M mutation, histone modifications, histone deacetylase inhibitors
- MeSH terms
- X-linked Nuclear Protein, Base Sequence, Child, Chromatin, DNA Mutational Analysis, DNA Helicases, Glioblastoma, Histones, Humans, Molecular Sequence Data, Mutation, Nuclear Proteins, Tumor Suppressor Protein p53, Telomere, Molecular Chaperones, Gene Expression Profiling, Chromatin Assembly and Disassembly, Adaptor Proteins, Signal Transducing, Co-Repressor Proteins, Exome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.